Crisp multiplication

Alnylam Pharmaceuticals Inc. has been in the clinic since 2005, but has now for the first time put forward a product development strategy that focuses on genetic diseases.

The company aims to get five RNAi products into late-stage clinical development by 2015. The idea is that targeting genetic diseases can yield reimbursable products for indications that can be served with a small internal sales force...